Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb

The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical...

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

In the second year of Endpoints News’ budding tradition of highlighting women blazing trails in biopharma R&D, we’ve seen a number of...

Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy

Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy...

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

By Ben Adams Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’...

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add...

Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel...

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform

with billions on the line A little more than a year after Celgene bellied up to the partnership table with $33 million in cash to ally...

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

by John Carroll Editor & Founder of ENDPOINTS Over the last 15 years I’ve had the chance to help select about 200 private biotechs for...

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.

Merck opts in for Dragonfly's TriNKET cancer immunotherapy program

The U.S. Big Pharma is getting its hands on its first TriNKET immunotherapy candidate from the biotech, which comes after the pair...

Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly

Dive Brief: Bristol Myers Squibb has licensed from privately held biotech Dragonfly Therapeutics an experimental immunotherapy that it...

Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology

With a potential IL-12 game-changer This morning Bristol Myers R&D maestro Rupert Vessey is taking the wraps off one of the biggest cash...

Doing deals in a time of coronavirus

Biotech CEO Bill Haney says 'you focus on the things that make a difference' Fidelity Management and Research has led a new round for...

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2...

Merck & Co. Partners with Dragonfly on NK-Based Cancer Immunotherapies

Merck & Co. plans to develop new solid tumor cancer immunotherapies using Dragonfly Therapeutics’ Tri-specific NK cell Engagement...

Dragonfly Founders to Lead Disruptors Conversation at Boston Biotech

Every life sciences startup aims to shake up and challenge the status quo. But which Boston companies are taking the most radical...

AbbVie selects target for Dragonfly partnership

Dragonfly’s partnership with AbbVie is beginning to bear fruit.

Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly

A little more than 2 years after Merck’s Roger Perlmutter signed off on a deal that would pay Dragonfly up to $695 million for each drug...

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License

For Dragonfly’s IL-12 Investigational Immunotherapy Program Agreement Includes DF6002, With Potential to Advance Treatment of Solid...

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate

Published: Aug 10, 2020 WALTHAM, Mass., Aug. 10, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc.. ("Dragonfly" or the "Company"), today...

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly...

Dragonfly Therapeutics in $695M cancer R&D pact with Merck

More than a year after insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with big biotech Celgene, it's back at...

Dragonfly and Merck Strike $695 Million Deal for Solid Tumors

Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license...

Celgene bags option on NK cell-based blood cancer assets

Celgene has landed an option on four natural killer (NK) cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics. The...